다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Pharmaceutical fronts : Chinese journal of pharmaceutical b, v.3 no.3, 2021년, pp.e129 - e137
Liu, Fei (State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China) , Liu, Xi-Zi (State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China) , Yang, Qian (State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China) , Han, Shi-Yi (State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China) , Fan, Si-Yang (State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China)
AI-Helper
Simultaneous oral intake of herbal medicine with chemical drugs may result in beneficial pharmacodynamic efficacy, including additive and synergistic effects with reduced toxicity. Gnaphalium affine D. Don (GAD) is a traditional Chinese Medicine that has been used for the management of hyperuricemia...
D Chen Chinese herbal medicines facilitate the control of chemotherapy-induced side effects in colorectal cancer: progress and perspective Front Pharmacol 2018 10.3389/fphar.2018.01442 9 1442
W Wang The role of Chinese herbal medicine in the management of adverse drug reactions of leflunomide in treating rheumatoid arthritis Phytomedicine 2020 10.1016/j.phymed.2019.153136 68 153136
X Luo The add-on effect of Chinese herbal medicine on COVID-19: a systematic review and meta-analysis Phytomedicine 2021 10.1016/j.phymed.2020.153282 85 153282
F Liu Hypouricemic activity of Gnaphalium affine D. Don [in Chinese] Shenyang Yaoke Daxue Xuebao 2020 01 37 12
W Zhang Chemical constituents from Gnaphalium affine and their xanthine oxidase inhibitory activity Chin J Nat Med 2018 05 16 347
H J Zhang Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis J Ethnopharmacol 2017 10.1016/j.jep.2017.03.057 203 304
C Li Extraction and purification of total flavonoids from Gnaphalium affine D. Don and their evaluation for free radicals' scavenging and oxidative damage inhabitation potential in mice liver Arab J Chem 2021 10.1016/j.arabjc.2021.103006 03 14 103006
L Jiang Protective effect of Gnaphalium tranzscelii against acute liver injury in mice [in Chinese] Shizhen Guo Yi Guo Yao 2008 08 19 1901
Chinese Society of Endocrinology CMA Guideline for the diagnosis and management of hyperuricemia and gout in China (2019) [in Chinese] Zhonghua Neifenmi Daixie Zazhi 2020 01 36 1
M H Lee A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008 10.2165/00002018-200831080-00002 08 31 643
W Parzefall Toxicological studies on a benzofurane derivative. I. A comparative study with phenobarbital on rat liver Toxicol Appl Pharmacol 1990 10.1016/0041-008X(90)90343-S 03 106 482
P Sun Benzbromarone aggravates hepatic steatosis in obese individuals Biochim Biophys Acta Mol Basis Dis 2018 10.1016/j.bbadis.2018.03.009 1864 2067
N Liu EGF receptor inhibition alleviates hyperuricemic nephropathy J Am Soc Nephrol 2015 10.1681/ASN.2014080793 11 26 2716
X Liu HPLC method for determination of uric acid in plasma of hyperuricemia model mice [in Chinese] Yaowu Pingjia Yanjiu 2017 03 40 319
T Dai Quantitative analysis in drug combination (author's transl) [in Chinese] Zhongguo Yaolixue Tongbao 1998 05 14 479
D Hoffmann Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity Toxicology 2010 10.1016/j.tox.2010.08.013 277 49
C Mende Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy Adv Ther 2015 10.1007/s12325-015-0272-7 12 32 1177
L Strilchuk Safety and tolerability of available urate-lowering drugs: a critical review Expert Opin Drug Saf 2019 10.1080/14740338.2019.1594771 04 18 261
P Richette Gout Lancet 2010 10.1016/S0140-6736(09)60883-7 375 318
L Billiet Review of hyperuricemia as new marker for metabolic syndrome ISRN Rheumatol 2014 10.1155/2014/852954 2014 852954
A Takemura Inhibition of biliary network reconstruction by benzbromarone delays recovery from pre-existing liver injury Toxicology 2019 10.1016/j.tox.2019.05.004 423 32
F Zhang Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: implication of herb-drug interactions in COVID-19 pharmacotherapy Food Chem Toxicol 2021 10.1016/j.fct.2021.111998 149 111998
F Zhang Herb-drug interaction between Styrax and warfarin: molecular basis and mechanism Phytomedicine 2020 10.1016/j.phymed.2020.153287 77 153287
K Kobayashi Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes Biopharm Drug Dispos 2012 10.1002/bdd.1813 08 33 466
M Yoshida Association of a reactive intermediate derived from 1′,6-dihydroxy metabolite with benzbromarone-induced hepatotoxicity J Biochem Mol Toxicol 2017 10.1002/jbt.21946 10 31 e21946
Y Kimura Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity Food Chem Toxicol 2010 10.1016/j.fct.2009.10.041 01 48 429
H Rastogi Evaluation of inhibitory effects of caffeic acid and quercetin on human liver cytochrome p450 activities Phytother Res 2014 10.1002/ptr.5220 12 28 1873
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.